Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
In SURMOUNT-1, 72 weeks of tirzepatide induced mean WL of 1622.5% in people without diabetes compared to 2.4% with placebo, with no sign of the weight plateauing, suggesting that there may be further WL with long-term use [46]
Semaglutide (Wegovy/Ozempic) is the closest FDA-approved alternative, targeting the GLP-1 receptor that tirzepatide also activates
CoverWell: A Safety Net for Patients and Providers in Peptide/GLP-1 and Regenerative Therapies Modern regenerative medicinecovering GLP-1s, peptides, stem cells, and exosomes offers life-changing possibilities in weight loss, longevity, recovery, and performance optimization
J.BiermaszN.et al (2015)
US$ 20.03
US$ 22.70
US$ 24.80
US$ 20.23
US$ 28.37
US$ 29.38
US$ 25.85
US$ 25.75
US$ 22.36
US$ 22.18
